ULBP1 anticorps (AA 26-216)

N° du produit ABIN7193457

Détail du produit anti-ULBP1 anticorps

Antigène: ULBP1 (UL16 Binding Protein 1 (ULBP1))

Épitope: AA 26-216

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ULBP1 est non-conjugé

Application: ELISA, Western Blotting (WB), Flow Cytometry (FACS)

Purification: purified

Immunogène: Purified recombinant fragment of human ULBP1 (AA: 26-216) expressed in E. coli.

Clone: 3A6F11

Isotype: IgG1

Information d'application

Indications d'application: WB:1:500 - 1:2000, FCM:1:200 - 1:400, ELISA:1:10000,

Restrictions: For Research Use only

Stockage

Buffer: Purified antibody in PBS with 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: 4°C, -20°C for long term storage

Détails sur ULBP1

Antigène: ULBP1 (UL16 Binding Protein 1 (ULBP1))

Autre désignation: ULBP1 (ULBP1 Produits)

Synonymes: anticorps RAET1I, anticorps A430108B07Rik, anticorps MULT1, anticorps ULBP1, anticorps UL16 binding protein 1, anticorps UL16 binding protein 21, anticorps NKG2D ligand 1, anticorps ULBP1, anticorps ULBP21, anticorps Ulbp1, anticorps LOC100683099

Sujet:

Description: The protein encoded by this gene is a ligand of natural killer group 2, member D (NKG2D), an immune system-activating receptor on NK cells and T-cells. Binding of the encoded ligand to NKG2D leads to activation of several signal transduction pathways, including those of JAK2, STAT5, ERK and PI3K kinase/Akt. Also, in cytomegalovirus-infected cells, this ligand binds the UL16 glycoprotein and is prevented from activating the immune system. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]

Aliases: N2DL-1, RAET1I, NKG2DL1

Poids moléculaire: 28 kDa

ID gène: 80329

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process